Authored by Innovative Science Solutions, now part of Lumanity

Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from the FDA is no small feat, even though the FDA has tried to simplify the process.

Applying for a COVID-19 Emergency Use Authorization (EUA) Letter from the US Food and Drug Administration (FDA) is no small feat, even though the FDA has tried to simplify the process to expedite the availability of diagnostic products, personal protective equipment (PPE), and therapeutics to handle the SARS-CoV-2 pandemic (you can find the FDA’s guidance here.) The upside is a less rigorous regulatory pathway and the ability to market your product prior to receiving full marketing approval. The downside is that the process itself is unfamiliar to most and has been modified more than once since initiation. Furthermore, there are a number of pitfalls or submission package deficiencies that can cause delays and/or rejection of the application.

Common pitfalls include inadequate testing procedures, failure to provide study protocols, presenting topline data only, and incomplete manufacturing data. Fortunately, many of these can be avoided by developing a complete submission package from the onset, rather than engaging in back and forth with the FDA regarding deficiencies, which can be time-consuming and delay time to market. For instance, when submitting an EUA package for a serological diagnostic, FDA requires a minimum number of positive and negative samples tested for every matrix (i.e. whole blood, serum, plasma) that the product is intended for. Many applicants only test whole blood but request authorization to market and label the test for all matrices.

The EUA regulatory pathway is not intended as a permanent solution, but rather as a temporary process to address a critical need. Once the EUA process for a particular category expires, all EUAs will become defunct and EUA products removed from the market unless applications have been submitted via the standard (i.e. long and laborious) regulatory pathways. Let Lumanity assist you in taking advantage of the EUA process now.

Lumanity has assisted with the submission of dozens of EUA packages, and not just for coronavirus-specific drugs, diagnostics, and devices. We’ve worked directly with the FDA on behalf of our clients (as authorized US agents) in order to address deficiencies or revise submissions based on evolving requirements. We know this process inside and out.

Complete the form to download our free white paper Applying for an FDA Coronavirus EUA Letter or contact us today to discuss how we can help.

Read the full whitepaper

To read the full whitepaper, please complete the form below.

Sign me up to receive regular insights from Lumanity
This field is for validation purposes and should be left unchanged.